Prospective validation of the prognostic 31‐gene expression profiling test in primary cutaneous melanoma

BACKGROUND: Gene expression profiling (GEP) has been integrated into cancer treatment decision‐making in multiple neoplasms. We prospectively evaluated the prognostic utility of the 31‐GEP test (DecisionDx‐Melanoma, Castle Biosciences, Inc) in cutaneous melanoma (CM) patients undergoing sentinel nod...

Descripción completa

Detalles Bibliográficos
Autores principales: Keller, Jennifer, Schwartz, Theresa L., Lizalek, Jason M., Chang, Ea‐sle, Patel, Ashaki D., Hurley, Maria Y., Hsueh, Eddy C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536922/
https://www.ncbi.nlm.nih.gov/pubmed/30950242
http://dx.doi.org/10.1002/cam4.2128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536922/
https://www.ncbi.nlm.nih.gov/pubmed/30950242
http://dx.doi.org/10.1002/cam4.2128

Ejemplares similares